Relapsed/Refractory Multiple Myeloma Treatment Decision Making : Episode 5

Navigating Bispecific Administration: Protocols, Dosage, and Challenges in R/R MM

January 25, 2024

By Amir Ali, PharmD, BCOP

Opinion

Video

Amir discusses challenges encountered during the administration process, offering valuable perspectives on the practical considerations and complexities in delivering these innovative therapies.

EP: 1.Case Presentation: Clinical Decision Making in a R/R MM patient

EP: 2.Treatment Options in Late Line Relapsed/Refractory MM Patients

EP: 3.Role of GPRC5D in R/R MM Patients

EP: 4.Case Presentation: Clinical Decision Making in a Patient With R/R MM

EP: 5.Navigating Bispecific Administration: Protocols, Dosage, and Challenges in R/R MM

EP: 6.Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D Bispecific

EP: 7.Case Presentation: Clinical Decision Making for a Patient With R/R MM

EP: 8.Patient-Centric Care in R/R MM

EP: 9.Guiding Through Challenges: Insights for Caregivers of R/R MM Patients

EP: 10.APPs Focus on Education of Talquetamab Use and Administration in Multiple Myeloma

Recent Videos

4 KOLs are featured in this series.

4 KOLs are featured in this series.

A panel of 5 experts on multiple myeloma

A panel of 5 experts on multiple myeloma

A panel of 4 experts on multiple myeloma

A panel of 4 experts on multiple myeloma

4 KOLs are featured in this series.

4 KOLs are featured in this series.

Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.

Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.

Related Content

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype

October 5th 2024

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP

September 30th 2024

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM

October 4th 2024

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Multiple myeloma

HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma

October 2nd 2024

Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.

Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma

Roman Fabbricatore

October 1st 2024

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.

Related Content

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype

October 5th 2024

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP

September 30th 2024

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM

October 4th 2024

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Multiple myeloma

HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma

October 2nd 2024

Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.

Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma

Roman Fabbricatore

October 1st 2024

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.